BOSTON--(BUSINESS WIRE)--InCrowd, pioneer of real-time market intelligence to the life sciences and healthcare industries, named longtime software as a service (SaaS) financial executive Rob Lubash as its new chief financial officer (CFO). Lubash will help InCrowd scale operations to meet strong demand for real-time market research technology solutions.
“Working at InCrowd provides me with the opportunity to use my experience to help advance an industry leader during an exciting period of unprecedented growth,” Lubash said. “I look forward to the challenge.”
With over 20 years of financial leadership experience, Lubash has assisted SaaS, software and technical services companies in a wide range of domains, from rapidly-growing start-ups to public companies. Previously, Lubash was CFO at Provant, a wellness solutions provider, in addition to Mobiquity, a digital professional services firm, and OutStart, a SaaS-based social and learning solutions provider. He possesses extensive experience raising capital, negotiating, and integrating acquisitions, including two successful exits and one IPO. A certified public accountant and chartered global management accountant Lubash has also served as a controller at ServiceSoft and Infinium.
“Rob has the rare ability to be both strategic and operational, to get things done as well as work with our board and management team on a wide range of financial leadership matters,” said Janet Kosloff, CEO and co-founder of InCrowd. “His guidance will be a huge asset to our team as we meet the needs of growing number of market researchers who see agile research as a strategic necessity to keeping their brands competitive.”
InCrowd provides a mobile microsurvey methodology and analytics engine that enables clients to reach targeted specialists and stakeholders easily among our extensive and diverse “Crowd” of healthcare professionals. These experts are available on-demand throughout the United States and around the globe, through the InCrowd platform, which is offered in 20 different languages. The brevity, speed, and simplicity of InCrowd’s approach has fundamentally changed the industry by providing quality data in situations where it was previously impossible to get timely market information. Nineteen of the top 20 pharmaceutical firms have relied upon InCrowd’s robust quality processes and verified experts to make fast, validated business decisions. For more information, visit www.incrowdnow.com.